Sou Hu Cai Jing·2025-05-06 10:18Core Viewpoint - Tiger Med's stock closed at 45.95 yuan, up 3.00%, with a rolling PE ratio of 118.45, marking a new low in 20 days, and a total market capitalization of 39.744 billion yuan [1] Company Summary - Tiger Med is a Contract Research Organization (CRO) that provides comprehensive clinical research solutions for global pharmaceutical and medical device innovation companies, focusing on new drug development [1] - The company's main services include clinical operations, clinical pharmacology, regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party audits and training, data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit of 165 million yuan, down 29.61% year-on-year, with a gross profit margin of 30.03% [1] Industry Summary - The average PE ratio for the medical services industry is 38.66, with a median of 38.36, placing Tiger Med at the 42nd position in the industry ranking [2] - The company has a total of 41,197 shareholders as of August 20, 2020, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]